报价延迟最少15分钟:2025/07/15 17:45 EDT
盘后时段
|
||||
|
11.61 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
11.61
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.28/-2.80
|
|
企业价值
263.08M
|
| 资产负债 |
|
每股账面净值
6.95
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/15 17:45 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which haveinitiated a Phase 3 clinical trial for hyperphagia associated with PWS. |
